Figure 2.

Percentage of responders based on a ≥2-point improvement on the Glabellar Line Scale (GLS) at maximum frown from Day 0 by investigator assessment: EVB-003 study, botulinumtoxinA-treated males only. Absolute percentage differences with 95% confidence intervals (CI) by visit were as follows:

Day Difference prabotulinumtoxinA - onabotulinumtoxinA (95% CI)

2 7.1% (−19.0 to 32.7)

14 −3.7% (−29.7 to 22.1)

30 25.2% (−1.5 to 48.8)

90 10.7% (−16.0 to 36.3)

120 6.3% (−19.7 to 31.9)

150 Not applicable